DE602005002562D1 - PYRROLYL SUBSTITUTED PYRIDOE2,3-DIPYRIMIDIN-7-ONE AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS - Google Patents

PYRROLYL SUBSTITUTED PYRIDOE2,3-DIPYRIMIDIN-7-ONE AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS

Info

Publication number
DE602005002562D1
DE602005002562D1 DE602005002562T DE602005002562T DE602005002562D1 DE 602005002562 D1 DE602005002562 D1 DE 602005002562D1 DE 602005002562 T DE602005002562 T DE 602005002562T DE 602005002562 T DE602005002562 T DE 602005002562T DE 602005002562 D1 DE602005002562 D1 DE 602005002562D1
Authority
DE
Germany
Prior art keywords
sup
pyridoe2
dipyrimidin
derivatives
therapeutic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602005002562T
Other languages
German (de)
Other versions
DE602005002562T2 (en
Inventor
Michelle M Bruendl
Rocco D Gogliotti
A P Goodman
Gregory Reichard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of DE602005002562D1 publication Critical patent/DE602005002562D1/en
Application granted granted Critical
Publication of DE602005002562T2 publication Critical patent/DE602005002562T2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The present invention provides pyrimidines of Formula I: wherein R<SUP>2</SUP>, R<SUP>4</SUP>, R<SUP>5</SUP>, R<SUP>6</SUP>, R<SUP>8 </SUP>and J have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
DE602005002562T 2004-05-04 2005-04-22 PYRROLYL SUBSTITUTED PYRIDOE2,3-DIPYRIMIDIN-7-ONE AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS Expired - Fee Related DE602005002562T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56790204P 2004-05-04 2004-05-04
US567902P 2004-05-04
PCT/IB2005/001141 WO2005105801A1 (en) 2004-05-04 2005-04-22 Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents

Publications (2)

Publication Number Publication Date
DE602005002562D1 true DE602005002562D1 (en) 2007-10-31
DE602005002562T2 DE602005002562T2 (en) 2008-01-31

Family

ID=34966564

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005002562T Expired - Fee Related DE602005002562T2 (en) 2004-05-04 2005-04-22 PYRROLYL SUBSTITUTED PYRIDOE2,3-DIPYRIMIDIN-7-ONE AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS

Country Status (10)

Country Link
US (1) US20080255162A1 (en)
EP (1) EP1749004B1 (en)
JP (1) JP2007536370A (en)
AT (1) ATE373659T1 (en)
BR (1) BRPI0510560A (en)
CA (1) CA2563669A1 (en)
DE (1) DE602005002562T2 (en)
ES (1) ES2292130T3 (en)
MX (1) MXPA06012829A (en)
WO (1) WO2005105801A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006302148B2 (en) * 2005-10-07 2012-12-06 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kalpha
NZ594628A (en) * 2005-10-07 2013-04-26 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITORS OF PI3Ka
WO2008021389A2 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
PT2074122E (en) 2006-09-15 2011-08-24 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
SI2139484T1 (en) * 2007-04-10 2013-10-30 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
CA2683784A1 (en) * 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido[2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
US20100209340A1 (en) * 2007-04-11 2010-08-19 Buhr Chris A Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
WO2009155121A2 (en) 2008-05-30 2009-12-23 Amgen Inc. Inhibitors of pi3 kinase
WO2010039740A1 (en) * 2008-09-30 2010-04-08 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011048936A1 (en) 2009-10-19 2011-04-28 大正製薬株式会社 Aminothiazole derivative
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
FR2955109B1 (en) 2010-01-08 2012-09-07 Sanofi Aventis 5-OXO-5,8-DIHYDRO-PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
US8901137B2 (en) 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
TR201813877T4 (en) 2012-02-10 2018-11-21 Hoffmann La Roche COMPOUNDS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY.
MX2014010176A (en) * 2012-02-23 2014-11-10 Abbvie Inc Pyridopyrimidinone inhibitors of kinases.
US9371336B2 (en) 2012-03-01 2016-06-21 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
KR102109992B1 (en) 2012-03-23 2020-05-13 피티씨 테라퓨틱스, 인크. Compounds for treating spinal muscular atrophy
WO2015105657A1 (en) 2013-12-19 2015-07-16 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
CA2954189A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
WO2016196386A1 (en) 2015-05-30 2016-12-08 Ptc Therapeutics, Inc. Methods for modulating rna splicing
LT3386511T (en) 2015-12-10 2021-08-25 Ptc Therapeutics, Inc. Methods for treating huntington`s disease
EA201991309A1 (en) 2016-11-28 2019-11-29 RNA SPLICING MODULATION METHODS
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
KR20200017476A (en) 2017-06-14 2020-02-18 피티씨 테라퓨틱스, 인크. How to Change RNA Splicing
CN111182898B (en) 2017-06-28 2024-04-16 Ptc医疗公司 Methods for treating huntington's disease
EP3645121A4 (en) 2017-06-28 2021-03-17 PTC Therapeutics, Inc. Methods for treating huntington's disease
US20210009590A1 (en) 2018-03-27 2021-01-14 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
EP3814360A1 (en) 2018-06-27 2021-05-05 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
EP3814357B1 (en) 2018-06-27 2024-05-01 PTC Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
CN114901659A (en) * 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 Fused pyrimidinone compounds as JAK inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100345830C (en) * 2000-04-27 2007-10-31 安斯泰来制药有限公司 Condensed heteroaryl derivatives
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones

Also Published As

Publication number Publication date
BRPI0510560A (en) 2007-11-20
EP1749004B1 (en) 2007-09-19
EP1749004A1 (en) 2007-02-07
ATE373659T1 (en) 2007-10-15
DE602005002562T2 (en) 2008-01-31
US20080255162A1 (en) 2008-10-16
JP2007536370A (en) 2007-12-13
CA2563669A1 (en) 2005-11-10
WO2005105801A1 (en) 2005-11-10
MXPA06012829A (en) 2007-01-26
ES2292130T3 (en) 2008-03-01

Similar Documents

Publication Publication Date Title
DE602005002562D1 (en) PYRROLYL SUBSTITUTED PYRIDOE2,3-DIPYRIMIDIN-7-ONE AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS
EA200700902A1 (en) 3-ARYLAMINOPYRIDINE DERIVATIVES
SE0401971D0 (en) Piperidne derivatives
MXPA05012894A (en) Tetrazol benzofurancarboxamides with p13k aktivity as therapeutic agents.
DE602005027707D1 (en) ISOINDOLIN COMPOUNDS AND ITS USES
IS8502A (en) Azate cyclic heterocycles as cannabinoid receptor antagonists
ATE407928T1 (en) AMINO-PHTALAZINONE DERIVATIVES, USE AS KINASE INHIBITORS, PRODUCTION AND PHARMACEUTICAL COMPOSITION
CY1110965T1 (en) ADDITIONAL HYPERPYROCYCLIC COMPOUNDS AND THEIR USE AS GLUTAMIC METHOD
ATE364605T1 (en) 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC ACTIVES WITH PI3K ACTIVITY
MXPA05009595A (en) 7-amino- isoindolyl compounds amd their pharmaceutical uses.
HK1097189A1 (en) Cannabinoid receptor ligands
EA200801998A1 (en) ПИРДДИН [3,4-b] ПИРАЗИНОНЫ
ATE452129T1 (en) N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES
EA025871B9 (en) Mek inhibitors and methods of using the same
ME00954B (en) Amino-heterocyclic compounds
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
ATE370139T1 (en) PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA INHIBITORS FOR THE TREATMENT OF CANCER
ATE537830T1 (en) NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTICS
ATE365735T1 (en) CYCLOALKYLSULFANYL-SUBSTITUTED BENZO BÖTHIOPHENE AS THERAPEUTIC AGENTS
MXPA05013061A (en) Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents.
CY1108932T1 (en) Compounds 4- (heterocyclyl) -benzenesulfoximine for the therapeutic treatment of inflammatory diseases
SE0402762D0 (en) Indazole sulphonamide derivatives
PE20050523A1 (en) PYRAZOLES AS TUMOR NECROSIS FACTOR INHIDORS
DE602006020295D1 (en) AZABENZIMIDALZOL DERIVATES, THEIR PREPARATION AND THEIR USE AS ANTICROBIAL AGENTS
SE0401970D0 (en) Novel compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee